A detailed history of Hexagon Capital Partners LLC transactions in Royalty Pharma PLC stock. As of the latest transaction made, Hexagon Capital Partners LLC holds 349 shares of RPRX stock, worth $9,457. This represents 0.0% of its overall portfolio holdings.

Number of Shares
349
Previous 336 3.87%
Holding current value
$9,457
Previous $8,000 12.5%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 08, 2024

BUY
$25.63 - $29.27 $333 - $380
13 Added 3.87%
349 $9,000
Q2 2024

Jul 12, 2024

SELL
$26.26 - $29.9 $2,836 - $3,229
-108 Reduced 24.32%
336 $8,000
Q1 2024

Apr 18, 2024

SELL
$27.46 - $31.33 $2,883 - $3,289
-105 Reduced 19.13%
444 $13,000
Q4 2023

Feb 05, 2024

SELL
$26.21 - $29.22 $1,808 - $2,016
-69 Reduced 11.17%
549 $15,000
Q3 2023

Oct 23, 2023

BUY
$26.26 - $31.38 $16,228 - $19,392
618 New
618 $16,000
Q3 2022

Oct 17, 2022

BUY
$39.88 - $44.65 $358 - $401
9 New
9 $0

Others Institutions Holding RPRX

About Royalty Pharma plc


  • Ticker RPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 437,139,008
  • Market Cap $11.8B
  • Description
  • Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic i...
More about RPRX
Track This Portfolio

Track Hexagon Capital Partners LLC Portfolio

Follow Hexagon Capital Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hexagon Capital Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hexagon Capital Partners LLC with notifications on news.